Condition: PCA · Prostate Cancer · Prostatic Neoplasm · Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection of prostate cancer (PCa).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of California Los Angeles | Los Angeles, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| Impression Imaging | Boca Raton, Florida, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
| UroPartners,LLC | Chicago, Illinois, United States | Recruiting |
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| Southern Urology | Lafayette, Louisiana, United States | Recruiting |
| Ochsner Clinic Foundation | New Orleans, Louisiana, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Weill Cornell | New York, New York, United States | Recruiting |
| MidLantic Urology | Philadelphia, Pennsylvania, United States | Recruiting |
| Atlantic Urology Specialists | Myrtle Beach, South Carolina, United States | Recruiting |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07052214